Engineering Conferences International

ECI Digital Archives
Cell Culture Engineering XVI

Proceedings

5-6-2018

Novel transposase tools for cell-line engineering
Ferenc Boldog
ATUM (formerly DNA2.0), USA, fboldog@atum.bio

Jeremy Minshull
ATUM (formerly DNA2.0), USA

Mark Welch
ATUM (formerly DNA2.0), USA

Kate Caves
ATUM (formerly DNA2.0), USA

Follow this and additional works at: http://dc.engconfintl.org/ccexvi
Part of the Engineering Commons
Recommended Citation
Ferenc Boldog, Jeremy Minshull, Mark Welch, and Kate Caves, "Novel transposase tools for cell-line engineering" in "Cell Culture
Engineering XVI", A. Robinson, PhD, Tulane University R. Venkat, PhD, MedImmune E. Schaefer, ScD, J&J Janssen Eds, ECI
Symposium Series, (2018). http://dc.engconfintl.org/ccexvi/53

This Abstract and Presentation is brought to you for free and open access by the Proceedings at ECI Digital Archives. It has been accepted for inclusion
in Cell Culture Engineering XVI by an authorized administrator of ECI Digital Archives. For more information, please contact franco@bepress.com.

Novel
Cell-Line
Development
NovelTransposases
Transposasesfor
for
Cell-Line
Development
&
Engineering
Ferenc Boldog*, Sowmya Rajendran, Kate Caves, Jeremy Minshull, Maggie Lee, Molly Hunter, James Love, Mark Welch
ATUM
DNA2.0),Rajendran,
Newark, CA
USA.Lee,
*fboldog@atum.bio
Ferenc (formerly
Boldog*, Sowmya
Maggie
Molly Hunter, Candice Talsalt, Lynn Webster, Vivi Truong, Elizabeth Hart,
Nicolay Kulikov, Thomas Purcell, Mark Welch, Miles Scotcher**, Claes Gustafsson*** and Jeremy Minshull
ATUM (formerly DNA2.0), Newark, CA USA. *fboldog@atum.bio, **miles@atum.bio, ***claes@atum.bio

Abstract

Leap-In transposase benefits

The generation of stable cell lines is critical for the
commercial production of protein therapeutics.
Current methodologies to introduce engineered
recombinant genes into production strains relies
on homologous recombination, a method limited
by poor integration rates (<<1%), concatemer
formation
and
common
transgene
rearrangements. To address this limitation, ATUM
has identiﬁed and engineered two orthologous
transposases, designated Leap-In 1 (from frog)
and Leap-In 2 (from insect), that stably integrate
synthetic transposons into the host genome with
close to 100% integration frequency and an
absolute minimum of concatemers or other
genetic instabilities. Each synthetic transposon
can encode up to 4 unique open reading frames
(ORFs) ﬂanked by inverted terminal repeats
recognized by the cognate transposase. Each
ORF is under discrete expression control thereby
enabling tuning of expression ratios by
adjustment of each ORF independently. Leap-In
transposases speed cell recovery times, enabling
the generation of high expressing stable pools (up
to 5g/L) in as little as 2 weeks post transfection.
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Leap-In transposase process
3

 Transposon and

transposase (as mRNA)
co-transfected into
target cell
 Broad host cell range
 ATUM uses 2 in-house

cell lines, both with full
traceability
 HD-BIOP3 GS null
(Horizon Discovery)
 DG44 DHFR null
(Prof. Lawrence
Chasin)

 No size limit for synthetic transposon.
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Stable pool ranking
Clonal cell line
generation
Stability testing

Shortened timelines
Transposases speed cell
pool recovery posttransfection.

 Multiple, parallel selection stringencies.
 High productivities in stable pools up to 5g/l
and clonal up to 6.5g/l.

Adjustment of expression ratios for 2-, 3- and 4-ORF vectors

2 ORFs

transposon are
independently
integrated by a “cut
and paste”
mechanism into
multiple sites across
the host genome
 48 hours post
transfection, no
mRNA or transposase
are detectable

Stable pools

Research Cell Bank

Application - optimized expression constructs

 Up to 4 open reading frames under
independent expression control.

 Single copies of entire

3 ORFs

HD-BIOP3 GS null CHO-K1 cell line from Horizon Discovery was co-transfected with
ATUM’s transposase and transposons with different vector and antibody
combinations to reach the highest speciﬁc productivity without compromising
product quality. Stable pools were established and productivity measured at day 14
in non-optimized small scale shake ﬂask or deep-well cultures.

Upper graph - Under typical selection conditions (strong GS promoter, 50 µM MSX), cell pools
created using tranposases recover viability >7 days faster than cell pools created by random
integration.
Lower graph - Under drug-free selection conditions (attenuated GS promoter), cell pools
created using transposases recover viability in ~ 3 weeks, whereas cell pools created by random
integration fail to recover.

4 ORFs

 Consistent ranking of highly productive
candidates = only a small number of clones
need to be screened.

 Product quality attributes are consistent
Two identical ORFs coding for a secreted protein were tagged with V5 (ORF1)
or FLAG (ORF2). A combination of vector elements were utilized to control
the ratio of expression of ORF2 to ORF1. Expression ratios of ORF2 : ORF1
between 2.5 : 1 and 1 : 1.5 were demonstrated.

3

ORFs encoding 3 or 4 ﬂuorescent proteins were cloned into six different 3-ORF vectors, and a single 4ORF vector. Fluorescence was measured at the stable pool stage. For the 3-ORF vector, various ratios
of all three ORFs were achieved. For the 4-ORF vector, a 4-fold range of expression was observed between the different ORFs.

from pools to clones, enabling early initiation
of process development and GLP-toxicology
studies.

Stable integration combined with structural integrity

Volumetric productivity
(mg/l)

Screening and selection of clones expressing transposon-based antibody construct



Top 166 clones from stable pools



Top 22 clones of previous 166



Top 8 clones of previous 22



20 days in static 96-well plate
with feeding



7 days in 24-deep well plate
fed batch culture



14 days in 125 ml ﬂask, fed
batch, non-optimized culture

1:1 correlation between copy number and speciﬁc productivity in transposase
mediated DG44 stable pools.

Clonal cell lines generated using Leap-In transposases exhibit
genetic stability and stable productivity over 60 population
doublings.
Over 96% of expression
cassettes integrated
into clones established
using hyperactive
transposases were
intact.
An antibody expression construct was transfected into HD-BIOP3 GS null CHOK1 cells (Horizon
Discovery) in the presence (+ transposase) or absence (- transposase) of Leap-In transposase.
Targeted Locus Ampliﬁcation was used to analyze the structural integrity of expression cassette
integrations.

Foot-print free excision of transposon from host genome.

Nine CHO GS KO clones, derived from the transposase-mediated integration of an antibody expression
cassette, were grown in 24-deep well plate for 60 generations (population doublings (PD)) in the presence (-Gln)
and absence (+Gln) of selection. Productivity and integrated copy number of clones after 60 PD were compared
to T0. No signiﬁcant change in productivity or copy number under the with glutamine (+Gln) and minus
glutamine (-Gln) growth conditions were observed compared to T0.

Excision efficiency of wild type and engineered hyperactive
Leap-In® 1 transposases

Stable pools derived from the transposase-mediated integration of an antibody expression cassette in DG44 cells, were grown under
fed-batch conditions. Productivity and copy number were measured. The correlation between copy number and speciﬁc
productivity indicates that each integrated copy is intact and functional.

Typical timeline of cell line development at ATUM

A synthetic transposon (RFP gene ﬂanked by
Leap-In 1 ITR’s inside a GFP gene ﬂanked by
Leap-In 2 ITR’s) was integrated into CHO cells
using Leap-In 2 transposase. Cells exhibited
red ﬂuorescence as RFP is expressed.

Cells transfected with Leap-In 1 mRNA.
Leap-In 1 transposase excised RFP at
cognate ITRs.

Cells exhibited green ﬂuorescence as
intact GFP is expressed
Hyperactive transposase variants




Studies are currently ongoing to demonstrate that integration of single
copies of transposons is possible.

Hyperactive transposase variants designed using ProteinGPS® demonstrate foot-print free excision. Variants
were ranked by excision efficiency measured as per ﬁgure on left. Different concentrations of hyperactive
transposase mRNA demonstrated a dose response. Hyperactive transposase variants tested show an
approximately 80-fold higher activity compared to wild type in this assay.



Stable pool-derived protein is available as early as 2 weeks post transfection.
Clonal cell line without stability information, available as early as 12 weeks post
-transfection.
RCBs (Research Cell Banks) released as early as 20 weeks post-transfection.

